Search Results - "Logroscino, G."

A community study outlines how to prevent Parkinson's disease motor complications in the clinic by Logroscino, G.

“…Click here to view the accompanying paper in this issue…”
Get full text

Bone substitutes in orthopaedic surgery: from basic science to clinical practice by Campana, V., Milano, G., Pagano, E., Barba, M., Cicione, C., Salonna, G., Lattanzi, W., Logroscino, G.

“…Bone substitutes are being increasingly used in surgery as over two millions bone grafting procedures are performed worldwide per year. Autografts still…”
Get full text

Early diagnosis of Alzheimer’s disease: the role of biomarkers including advanced EEG signal analysis. Report from the IFCN-sponsored panel of experts by Rossini, P.M., Di Iorio, R., Vecchio, F., Anfossi, M., Babiloni, C., Bozzali, M., Bruni, A.C., Cappa, S.F., Escudero, J., Fraga, F.J., Giannakopoulos, P., Guntekin, B., Logroscino, G., Marra, C., Miraglia, F., Panza, F., Tecchio, F., Pascual-Leone, A., Dubois, B.

“…•This review describes an integrated and multidisciplinary approach for the “early” diagnosis of Alzheimer's disease (AD).•An overview of epidemiology, genetic…”
Get full text

Dementias across continents: the Global Burden of Disease study by Logroscino, G

Get full text

Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature by Chiò, A, Logroscino, G, Traynor, B J, Collins, J, Simeone, J C, Goldstein, L A, White, L A

“…Amyotrophic lateral sclerosis (ALS) is relatively rare, yet the economic and social burden is substantial. Having accurate incidence and prevalence estimates…”
Get more information

Coffee, tea, and caffeine consumption and prevention of late-life cognitive decline and dementia: A systematic review by Panza, Francesco, Solfrizzi, V, Barulli, M. R, Bonfiglio, C, Guerra, V, Osella, A, Seripa, D, Sabbà, C, Pilotto, A, Logroscino, G

“…A prolonged preclinical phase of more than two decades before the onset of dementia suggested that initial brain changes of Alzheimer’s disease (AD) and the…”
Get full text

Incidence of amyotrophic lateral sclerosis in Europe by Logroscino, Giancarlo, Traynor, Bryan J, Hardiman, Orla, Chiò, Adriano, Mitchell, Douglas, Swingler, Robert J, Millul, Andrea, Benn, Emma, Beghi, Ettore

“…BackgroundGeographical differences in the incidence of amyotrophic lateral sclerosis (ALS) have been reported in the literature but comparisons across previous…”
Get full text

Estimating risk for developing epilepsy: A population-based study in Rochester, Minnesota by HESDORFFER, D. C, LOGROSCINO, G, BENN, E. K. T, KATRI, N, CASCINO, G, HAUSER, W. A

“…Previous studies that have assessed the risk of developing epilepsy have failed to account for the competing risk of death, significant in the elderly where…”
Get full text

Carbonated hydroxyapatite as bone substitute by Landi, E., Celotti, G., Logroscino, G., Tampieri, A.

“…B-carbonateapatite (CHA) powder was synthesized starting from calcium nitrate tetrahydrate, diammonium hydrogen phosphate and sodium hydrogen carbonate. The…”
Get full text

Mild cognitive impairment and early Alzheimer's disease eligibility for disease modification therapies in a tertiary centre for cognitive disorders: A simultaneous real‐word study on aducanumab and lecanemab by Logroscino, G., Urso, D., Gnoni, V., Giugno, A., Vilella, D., Castri, A., Barone, R., Nigro, S., Zecca, C., De Blasi, R., Introna, A.

“…Abstract Background and purpose The Food and Drug Administration approved two disease‐modifying treatments (DMTs) for Alzheimer's disease (AD), aducanumab and…”
Get full text

Descriptive epidemiology of amyotrophic lateral sclerosis: new evidence and unsolved issues by Logroscino, G, Traynor, B J, Hardiman, O, Chio’, A, Couratier, P, Mitchell, J D, Swingler, R J, Beghi, E

“…Amyotrophic lateral sclerosis (ALS) is a relatively rare disease with a reported population incidence of between 1.5 and 2.5 per 100 000 per year. Over the…”
Get full text

Elevated cerebrospinal fluid neurofilament light levels in patients with amyotrophic lateral sclerosis: a possible marker of disease severity and progression by Tortelli, R., Ruggieri, M., Cortese, R., D'Errico, E., Capozzo, R., Leo, A., Mastrapasqua, M., Zoccolella, S., Leante, R., Livrea, P., Logroscino, G., Simone, I. L.

“…Background To date there are no biomarkers with proven reliability as a measure of disease burden in amyotrophic lateral sclerosis (ALS). The aim of our study…”
Get full text

Reduced frequency of ALS in an ethnically mixed population: A population-based mortality study by ZALDIVAR, T, GUTIERREZ, J, LARA, G, CARBONARA, M, LOGROSCINO, G, HARDIMAN, O

“…To describe ALS mortality rates in the well-characterized ethnically mixed Cuban population over a 6-year period. There have been few population-based…”
Get full text

Prognosis of status epilepticus: role of aetiology, age, and consciousness impairment at presentation by Rossetti, A O, Hurwitz, S, Logroscino, G, Bromfield, E B

“…Background: Identification of outcome-predictive factors could lower risk of under- or over-treatment in status epilepticus (SE). Older age and acute…”
Get full text

Incidence of ALS in lombardy, Italy by BEGHI, E, MILLUL, A, MICHELI, A, VITELLI, E, LOGROSCINO, G

“…To assess the incidence and trends of ALS in a large population at risk. This study was performed in nine provinces of Lombardy in Northern Italy (population…”
Get full text

Incidence and lifetime risk of motor neuron disease in the United Kingdom: a population-based study by Alonso, A., Logroscino, G., Jick, S. S., Hernán, M. A.

“…Background and purpose:  To estimate the incidence and lifetime risk of motor neuron disease (MND) in a population‐based sample in the United Kingdom…”
Get full text

Status epilepticus : An independent outcome predictor after cerebral anoxia by ROSSETTI, A. O, LOGROSCINO, G, LIAUDET, L, RUFFIEUX, C, RIBORDY, V, SCHALLER, M. D, DESPLAND, P. A, ODDO, M

“…Prognosis of status epilepticus (SE) depends on its cause, but there is uncertainty as to whether SE represents an independent outcome predictor for a given…”
Get full text

Cerebrospinal fluid neurofilament light chain levels: marker of progression to generalized amyotrophic lateral sclerosis by Tortelli, R., Copetti, M., Ruggieri, M., Cortese, R., Capozzo, R., Leo, A., D'Errico, E., Mastrapasqua, M., Zoccolella, S., Pellegrini, F., Simone, I. L., Logroscino, G.

“…Background and purpose To evaluate whether cerebrospinal fluid (CSF) neurofilament light chain (NFL) levels could predict the time to generalization (TTG) in…”
Get full text

Analysis of survival and prognostic factors in amyotrophic lateral sclerosis: a population based study by Zoccolella, S, Beghi, E, Palagano, G, Fraddosio, A, Guerra, V, Samarelli, V, Lepore, V, Simone, I L, Lamberti, P, Serlenga, L, Logroscino, G

“…Objective:To measure survivorship and predictors of prognosis of amyotrophic lateral sclerosis (ALS).Methods:Incident cases, diagnosed in the 1998–1999 period…”
Get full text

Status Epilepticus: different venues, different resources, but similar prognosis by Logroscino, G.

Get full text